This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics

Register by January 24 to save up to $300

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Tomomi Sato
Associate Director at Takeda Pharmaceutical Company Limited
Speaker

Profile

Tomomi Sato is an Associate Director in Drug Product and Device Development at Takeda Pharmaceutical Company Limited, with over 15 years of experience in drug product development, particularly in parenteral and combination products. Tomomi’s career spans roles in Japan, Denmark, and the US, contributing to numerous projects involving oligonucleotides, peptides, biologics, antibody-drug conjugates (ADC), and combination products. Key skills include formulation/process development, clinical trial material (CTM) manufacturing, and regulatory documentation for IND/CTA and NDA/BLA submissions.

Tomomi is the project lead for a lipid nanoparticle (LNP) project under the Japan Pharmaceutical Manufacturers Association (JPMA).

Agenda Sessions

  • Key Points in Oligonucleotide Formulation Development, AI/ML-Driven LNP Development, and Scale-Up: General Overview and Case Studies

    9:15am